Why the study?
Does verapamil 360 mg/day reduce death and reinfarction in patients after an acute myocardial infarction?
Population
Patients after an acute myocardial infarction (pooled from two trials, DAVIT I and II)
Comparison
Verapamil 360 mg/day starting from the 2nd week… vs Placebo
Design
Meta-analysis, randomized, double-blind
Authors
Loading...
Supports verapamil 360 mg/day from week 2 post-MI to cut death and reinfarction; confirms pooled benefit in secondary prevention.
Does verapamil 360 mg/day reduce death and reinfarction in patients after an acute myocardial infarction?
Verapamil 360 mg/day initiated in the second week after an acute myocardial infarction significantly reduces the risk of death and reinfarction.
Jørgen Fischer Hansen (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: